Schedule 13D/A

Filed by: BLUE OCEAN STRUCTURE INVESTMENT COMPANY LTD
Total Shares: 79,528,662
Subject Company: Global Cord Blood Corp - View Complete Ownership History Backtest
Filed as of Date: 05/20/2022
Event Date: 05/20/2022
Overall % Ownership: 65.4
Theoretical performance if you bought this security on the day the filing was released.
Perf 1d Perf 5d Perf 1m Perf 6m Perf 1y Max Gain # Days to Max Gain Max Loss # Days to Max Loss
-1.9608 -3.5294 10.5882 36.8627 21 -8.2353 4

Reporting Persons

Name Sole
Voting Power
Shared
Voting Power
Sole
Dispositive Power
Shared
Dispositive Power
Aggregate
Amount Owned
Percent
of class
Blue Ocean Structure Investment Co Ltd 0 79,528,662 0 79,528,662 79,528,662 65.4%
Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership) 0 79,528,662 0 79,528,662 79,528,662 65.4%
Nanjing Ying Peng Asset Management Co, Ltd 0 79,528,662 0 79,528,662 79,528,662 65.4%
Yafei Yuan 0 79,528,662 0 79,528,662 79,528,662 65.4%
Dendreon Pharmaceuticals LLC 0 0 0 0 0
Nanjing Xinjiekou Department Store Co, Ltd 0 0 0 0 0
Sanpower Group Co, Ltd 0 79,528,662 0 79,528,662 79,528,662 65.4%
View Original Filing on Edgar's

Raw Filing Contents

0001104659-22-063440.txt : 20220520
0001104659-22-063440.hdr.sgml : 20220520
20220520170016
ACCESSION NUMBER:		0001104659-22-063440
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220520
DATE AS OF CHANGE:		20220520
GROUP MEMBERS:		DENDREON PHARMACEUTICALS LLC
GROUP MEMBERS:		NANJING XINJIEKOU DEPARTMENT STORE CO., LTD.
GROUP MEMBERS:		NANJING YING PENG ASSET MANAGEMENT CO., LTD
GROUP MEMBERS:		NANJING YING PENG HUI KANG MEDICAL INDUSTRY INVESTMENT PARTNERSHIP (LIMITED PARTNERSHIP)
GROUP MEMBERS:		SANPOWER GROUP CO., LTD.
GROUP MEMBERS:		YAFEI YUAN

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Global Cord Blood Corp
		CENTRAL INDEX KEY:			0001467808
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-84917
		FILM NUMBER:		22948521

	BUSINESS ADDRESS:	
		STREET 1:		48 FL., BANK OF CHINA TOWER
		STREET 2:		1 GARDEN ROAD
		CITY:			CENTRAL HONG KONG
		STATE:			K3
		ZIP:			000000
		BUSINESS PHONE:		852-3605-8180

	MAIL ADDRESS:	
		STREET 1:		48 FL., BANK OF CHINA TOWER
		STREET 2:		1 GARDEN ROAD
		CITY:			CENTRAL HONG KONG
		STATE:			K3
		ZIP:			000000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	China Cord Blood Corp
		DATE OF NAME CHANGE:	20090707

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Blue Ocean Structure Investment Co Ltd
		CENTRAL INDEX KEY:			0001729271
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		VISTRA CORPORATE SERVICE CENTRE
		STREET 2:		WICKHAMS CAY II, ROAD TOWN
		CITY:			TORTOLA
		STATE:			D8
		ZIP:			VG1110
		BUSINESS PHONE:		86(25)83274711

	MAIL ADDRESS:	
		STREET 1:		VISTRA CORPORATE SERVICE CENTRE
		STREET 2:		WICKHAMS CAY II, ROAD TOWN
		CITY:			TORTOLA
		STATE:			D8
		ZIP:			VG1110
SC 13D/A 1 tm2216221d1_sc13da.htm SC 13D/A

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Schedule 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

 

GLOBAL CORD BLOOD CORPORATION

(Name of Issuer)

 

Ordinary Shares, $0.0001 par value

(Title of Class of Securities)

 

G21107100 

(CUSIP Number)

 

Cheng Zeng

No. 68 Software Avenue, Yuhuatai District

Nanjing, China

+86-25-83274734

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

May 20, 2022

(Date of Event Which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. G21107100  

 

1.

NAME OF REPORTING PERSON:

Blue Ocean Structure Investment Co Ltd

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨
(b) ¨

3.

SEC USE ONLY

 

4.

SOURCE OF FUNDS

AF

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e): ¨
6.

CITIZENSHIP OR PLACE OF ORGANIZATION

British Virgin Islands

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH
7.

SOLE VOTING POWER

0

8.

SHARED VOTING POWER

79,528,662

9.

SOLE DISPOSITIVE POWER

0

10.

SHARED DISPOSITIVE POWER

79,528,662

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

79,528,662

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

¨

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

65.4%(1)

 

14.

TYPE OF REPORTING PERSON

CO

       

(1) Based on 121,551,075 shares outstanding as of December 31, 2021 pursuant to the Issuer’s Form 6-K filed with the SEC on February 28, 2022.

 

 

 

 

CUSIP No. G21107100  

 

1.

NAME OF REPORTING PERSON:

Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership)

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨
(b) ¨

3.

SEC USE ONLY

 

4.

SOURCE OF FUNDS

OO

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e): ¨
6.

CITIZENSHIP OR PLACE OF ORGANIZATION

People’s Republic of China

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH
7.

SOLE VOTING POWER

0

8.

SHARED VOTING POWER

79,528,662

9.

SOLE DISPOSITIVE POWER

0

10.

SHARED DISPOSITIVE POWER

79,528,662

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

79,528,662

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

x

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

65.4%(2) 

 

14.

TYPE OF REPORTING PERSON

PN

       

(2) Based on 121,551,075 shares outstanding as of December 31, 2021 pursuant to the Issuer’s Form 6-K filed with the SEC on February 28, 2022.

 

 

 

 

CUSIP No. G21107100  

 

1.

NAME OF REPORTING PERSON:

Nanjing Ying Peng Asset Management Co., Ltd.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨
(b) ¨

3.

SEC USE ONLY

 

4.

SOURCE OF FUNDS

AF

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e): ¨
6.

CITIZENSHIP OR PLACE OF ORGANIZATION

People’s Republic of China

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH
7.

SOLE VOTING POWER

0

8.

SHARED VOTING POWER

79,528,662

9.

SOLE DISPOSITIVE POWER

0

10.

SHARED DISPOSITIVE POWER

79,528,662

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

79,528,662

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

x

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

65.4%(3)

 

14.

TYPE OF REPORTING PERSON

CO

       

(3) Based on 121,551,075 shares outstanding as of December 31, 2021 pursuant to the Issuer’s Form 6-K filed with the SEC on February 28, 2022.

 

 

 

 

CUSIP No. G21107100  

 

1.

NAME OF REPORTING PERSON:

Yafei Yuan

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨
(b) ¨

3.

SEC USE ONLY

 

4.

SOURCE OF FUNDS

OO

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e): ¨
6.

CITIZENSHIP OR PLACE OF ORGANIZATION

People’s Republic of China

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH
7.

SOLE VOTING POWER

0

8.

SHARED VOTING POWER

79,528,662

9.

SOLE DISPOSITIVE POWER

0

10.

SHARED DISPOSITIVE POWER

79,528,662

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

79,528,662

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

¨

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

65.4%(4)

 

14.

TYPE OF REPORTING PERSON

IN

       

(4) Based on 121,551,075 shares outstanding as of December 31, 2021 pursuant to the Issuer’s Form6-K filed with the SEC on February 28, 2022.

 

 

 

 

CUSIP No. G21107100  

 

1.

NAME OF REPORTING PERSON:

Dendreon Pharmaceuticals LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨
(b) ¨

3.

SEC USE ONLY

 

4.

SOURCE OF FUNDS

OO

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e): ¨
6.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
7.

SOLE VOTING POWER

0

8.

SHARED VOTING POWER

0

9.

SOLE DISPOSITIVE POWER

0

10.

SHARED DISPOSITIVE POWER

0

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

¨

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

0

 

14.

TYPE OF REPORTING PERSON

OO

       

 

 

 

 

CUSIP No. G21107100  

 

1.

NAME OF REPORTING PERSON:

Nanjing Xinjiekou Department Store Co., Ltd.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨
(b) ¨

3.

SEC USE ONLY

 

4.

SOURCE OF FUNDS

OO

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e): ¨
6.

CITIZENSHIP OR PLACE OF ORGANIZATION

People’s Republic of China

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH
7.

SOLE VOTING POWER

0

8.

SHARED VOTING POWER

0

9.

SOLE DISPOSITIVE POWER

0

10.

SHARED DISPOSITIVE POWER

0

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

¨

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

0

 

14.

TYPE OF REPORTING PERSON

CO

       

 

 

 

 

CUSIP No. G21107100  

 

1.

NAME OF REPORTING PERSON:

Sanpower Group Co., Ltd.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨
(b) ¨

3.

SEC USE ONLY

 

4.

SOURCE OF FUNDS

OO

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e): ¨
6.

CITIZENSHIP OR PLACE OF ORGANIZATION

People’s Republic of China

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
7.

SOLE VOTING POWER

0

8.

SHARED VOTING POWER

79,528,662

9.

SOLE DISPOSITIVE POWER

0

10.

SHARED DISPOSITIVE POWER

79,528,662

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

79,528,662

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

¨

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

65.4%*

14.

TYPE OF REPORTING PERSON

CO

       

 

(*) Based on 121,551,075 shares outstanding as of December 31, 2021 pursuant to the Issuer’s Form 6-K filed with the SEC on February 28, 2022.

 

 

 

 

INTRODUCTORY NOTE

 

This Amendment No. 3 to Schedule 13D (this “Amendment No. 3”) related to the Schedule 13D filed on February 8, 2018, as amended prior to this Amendment No. 3 (as so amended, the “Schedule 13D”) with respect to the ordinary shares, par value $0.0001 per share (the “Shares”), of Global Cord Blood Corporation, an exempted company incorporated under the laws of the Cayman Islands (the “Issuer”). Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Except as otherwise specified in this Amendment No. 3, all items in the Schedule 13D are unchanged. All capitalized terms used in this Amendment No. 3 and not otherwise defined herein have the meaning ascribed to such terms in the Schedule 13D.

 

ITEM 2. IDENTITY AND BACKGROUND

 

The following paragraph amends and restates in its entirety the first paragraph of Item 2 of the Schedule 13D:

 

This Statement is filed by Blue Ocean Structure Investment Co Ltd (the “Investor”), a company incorporated in the British Virgin Islands, Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership) (the “Fund”), an indirect parent beneficially owning 100% of the outstanding shares of the Investor and a limited partnership incorporated in the People’s Republic of China (“PRC”), Nanjing Ying Peng Asset Management Co., Ltd., a company incorporated in the PRC (the “GP”), Mr. Yafei Yuan, a PRC citizen (“Mr. Yuan”), Dendreon Pharmaceuticals LLC, a Delaware limited liability company (“Dendreon”), that is wholly owned by Nanjing Xinjiekou Department Store Co., Ltd., a company incorporated in the PRC (“Cenbest”), that is controlled by Sanpower Group Co., Ltd., a company incorporated in the PRC and is indirectly controlled by Mr. Yuan (“Sanpower”, and together with the Investor, the Fund, the GP, Mr. Yuan, Dendreon, and Cenbest, the “Reporting Persons”).  The principal business address of the Investor is Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG110, British Virgin Islands. The principal business address of the Fund is No. 68 Software Avenue, Yuhuatai District, Nanjing, China. The principal business address of the GP is No. 68 Software Avenue, Yuhuatai District, Nanjing, China.  The principal business address of Mr. Yuan is No. 68 Software Avenue, Yuhuatai District, Nanjing, China. The principal business address of Dendreon is 1700 Saturn Way, Seal Beach, California 90740. The principal business address of Cenbest is No. 1 Zhongshannan Road, Qinhuai District, Nanjing, China. The principal business address of Sanpower is No. 68 Software Avenue, Yuhuatai District, Nanjing, China.

 

ITEM 4. PURPOSE OF TRANSACTION

 

The following paragraph is added as the penultimate paragraph of Item 4 of the Schedule 13D:

 

On May 17, 2022, Dendreon entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with AMC Fund, L.P., a Delaware limited partnership (the “Seller”). Pursuant to the Stock Purchase Agreement, Dendreon has agreed to purchase from the Seller 2,000,000 ordinary shares, par value $0.0001 per share of the Issuer for an aggregate purchase price of $13,000,000, subject to certain conditions set forth in the Stock Purchase Agreement. The Stock Purchase Agreement is attached hereto as Exhibit A and incorporated herein by reference.

 

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

 

The following amends and restates in its entirety (a) and (b) of Item 5 of the Schedule 13D:

 

(a) and (b)

 

The information set forth in the cover pages and Item 3 of this Statement is incorporated herein by reference.

 

As of the date hereof, the Investor owns on record 77,260,927 Shares and beneficially owns 79,528,662 Shares. By virtue of the relationships described in Item 2 of this Statement, each of the Investor, the Fund, the GP, Mr. Yuan and Sanpower may be deemed to beneficially own the Shares owned by the Investor.

 

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

 

Exhibit A – Stock Purchase Agreement

 

 

 

 

  Blue Ocean Structure Investment Co Ltd
     
  By:   /s/ Xiaoyang Chen 
  Name: Xiaoyang Chen
  Title: Director
     
  Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership)
     
  By:   /s/ Lei Wang 
  Name: Lei Wang
  Title: Authorized Signatory
     
  Nanjing Ying Peng Asset Management Co., Ltd.
     
  By:   /s/ Lei Wang 
  Name: Lei Wang
  Title: Executive Director
     
  YAFEI YUAN
     
  By:   /s/ Yafei YUAN 
  Name: Yafei YUAN
     
  Dendreon Pharmaceuticals LLC
     
  By:   /s/ Yong Zhang
 

Name: Yong Zhang

Title: Chief Executive Officer

     
  Nanjing Xinjiekou Department Store Co., Ltd.
     
  By:   /s/ Lingyun Zhai
 

Name: Lingyun Zhai

Title: Chairman of the Board

   
  Sanpower Group Co., Ltd.
     
  By:   /s/ Yafei Yuan
 

Name: Yafei Yuan

Title: Chairman of the Board

   

 

 

 

 

AGREEMENT OF JOINT FILING

 

The parties listed below agree that the amendment of Schedule 13D to which this agreement is attached as an exhibit, shall be filed on behalf of each of them. This Agreement is intended to satisfy Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

Dated: May 20, 2022

 

[Signature Page to Joint Filing Agreement]

 

 

 

 

  Blue Ocean Structure Investment Co Ltd
     
  By:   /s/ Xiaoyang Chen 
  Name: Xiaoyang Chen
  Title: Director
     
  Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership)
     
  By:   /s/ Lei Wang 
  Name: Lei Wang
  Title: Authorized Signatory
     
  Nanjing Ying Peng Asset Management Co., Ltd.
     
  By:   /s/ Lei Wang 
  Name: Lei Wang
  Title: Executive Director
     
  YAFEI YUAN
     
  By:   /s/ Yafei YUAN 
  Name: Yafei YUAN
     
  Dendreon Pharmaceuticals LLC
     
  By:   /s/ Yong Zhang 
  Name: Yong Zhang
  Title: Chief Executive Officer
     
  Nanjing Xinjiekou Department Store Co., Ltd.
     
  By:   /s/ Lingyun Zhai 
  Name: Lingyun Zhai
  Title: Chairman of the Board
     
  Sanpower Group Co., Ltd.
     
  By:   /s/ Yafei Yuan 
  Name: Yafei Yuan
  Title: Chairman of the Board

 

 

 

WhaleWisdom Logo

Elevate your investments